Liver transplantation for an infant with neonatal intrahepatic cholestasis caused by citrin deficiency using heterozygote living donor
Version of Record online: 6 APR 2009
© 2009 John Wiley & Sons A/S
Volume 14, Issue 7, pages E86–E88, November 2010
How to Cite
Shigeta, T., Kasahara, M., Kimura, T., Fukuda, A., Sasaki, K., Arai, K., Nakagawa, A., Nakagawa, S., Kobayashi, K., Soneda, S. and Kitagawa, H. (2010), Liver transplantation for an infant with neonatal intrahepatic cholestasis caused by citrin deficiency using heterozygote living donor. Pediatric Transplantation, 14: E86–E88. doi: 10.1111/j.1399-3046.2009.01172.x
- Issue online: 6 APR 2009
- Version of Record online: 6 APR 2009
- Accepted for publication 23 January 2009
- neonatal intrahepatic cholestasis caused by citrin deficiency;
- living donor liver transplantation;
- adult-onset type II citrullinemia;
- heterozygote donor;
- end-stage liver disease
Shigeta T, Kasahara M, Kimura T, Fukuda A, Sasaki K, Arai K, Nakagawa A, Nakagawa S, Kobayashi K, Soneda S, Kitagawa H. Liver transplantation for an infant with neonatal intrahepatic cholestasis caused by citrin deficiency using heterozygote living donor. Pediatr Transplantation 2010: 14:E86–E88. © 2009 John Wiley Sons & A/S.
Abstract: NICCD is an autosomal recessive genetic disorder, characterized by cholestasis, coagulopathy, hypoglycemia, fatty liver and multiple amino acidemia. NICCD develops in the neonatal/infantile period and has been reported as a “naturally curable” disease within one yr of life. Recently, we experienced an infantile NICCD who developed progressive liver failure, and required subsequent LT using a heterozygote living donor at eight months of age. Diagnosis of NICCD was established before transplantation, and donor evaluation included mutation in the SLC25A13 gene for exclusion of individuals with citrin deficiency citrullinemia. LDLT, from blood type identical mother using a left lateral segment graft, was performed without serious complication. Plasma amino acid concentration was normalized rapidly, and the patient was discharged 30 days after transplant. During one yr follow up, the recipient has been doing well without additional medication for NICCD. NICCD should be considered in the differential diagnosis as a cause of neonatal/infantile cholestatic disease. LT using a heterozygote living donor is an effective alternative in countries where a deceased donor is not available.